MA
AUPH icon

MYDA Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

MYDA Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,000
Closed -$310K – 262
2021
Q3 		$310K Buy
+14,000
New +$222K 0.09% 189

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.05B AUM 111.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MYDA Advisors's AUPH Position: Q4 2021 in Review

MYDA Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 14,000 shares — an estimated $310K sold.

MYDA Advisors first reported a position in AUPH in Q3 2021 and held it in 1 quarter. The position peaked at $310K in Q3 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

  • MYDA Advisors reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • MYDA Advisors sold 14,000 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $310K.
  • MYDA Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • MYDA Advisors's Aurinia Pharmaceuticals position peaked at $310K in Q3 2021.
  • 191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on MYDA Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.